While at Reuters Pharma Europe in Barcelona the other week, pharmaphorum web editor Nicole Raleigh spoke with Florian Schnappauf, VP of enterprise commercial strategy at Veeva Europe, about
Clinical research continues to struggle with a lack of representation within trial populations, and gender diversity in clinical trials remains a critical issue.
AI and wearable medical devices are already advancing patient care, and transformative use of data and digital innovation is set to enable a new generation of medicines, faster.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh